Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2229808 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2NPSR1CYP19A1KDM4E | |
| SCHEMBL2229998 | 0.98 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2NPSR1CYP19A1KDM4E | |
| SCHEMBL20237949 | 0.95 | CYP19A1 (0.50) | ALDH1A1SMN1; SMN2NPSR1CYP19A1KDM4E | |
| SCHEMBL20804350 | 0.91 | COMT (0.53) | ALDH1A1SMN1; SMN2CYP19A1MAPTCOMT | |
| SCHEMBL28024574 | 0.91 | COMT (0.53) | ALDH1A1SMN1; SMN2CYP19A1MAPTCOMT | |
| SCHEMBL2227787 | 0.84 | KDM4E (0.58) | ALDH1A1KDM4EPOLBTNKSPARP1 | |
| SCHEMBL20407941 | 0.83 | HRH3 (0.56) | SMN1; SMN2NPSR1 | |
| SCHEMBL22642414 | 0.83 | COMT (0.48) | ALDH1A1SMN1; SMN2CYP19A1MAPTCOMT | |
| SCHEMBL20381979 | 0.83 | KMT2A (0.60) | ALDH1A1SMN1; SMN2CYP19A1MAPTCOMT | |
| SCHEMBL31256884 | 0.83 | LMNA (0.57) | ALDH1A1SMN1; SMN2CYP19A1MAPTCOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| EP-2598483-B1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9663496-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9469710-B2 | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | MIDCAP FINANCIAL TRUST | 2016-08-11 | — | — | US | disclosed |
| US-9266856-B2 | AMPK—activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2382240-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | Bridgestone Corporation (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011091346-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2011-07-28 | — | — | WO | disclosed |
| WO-2010085622-A9 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010085622-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2010-07-29 | — | — | WO | disclosed |
| US-6906075-B2 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORP. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| EP-1465888-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003059289-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229838-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885SMN1; SMN2 2965/4885NPSR1 3471/4885 |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | MCHR1, MCHR2, MC1R | ALDH1A1 1474/4885SMN1; SMN2 1505/4885NPSR1 71/4885 |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885SMN1; SMN2 2965/4885NPSR1 3471/4885 |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | ALDH1A1 800/4885SMN1; SMN2 4028/4885NPSR1 1062/4885 |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, LIPC, PNLIP | ALDH1A1 800/4885SMN1; SMN2 4028/4885NPSR1 1062/4885 |
| US-10941134-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885SMN1; SMN2 2965/4885NPSR1 3471/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 807/4885SMN1; SMN2 2965/4885NPSR1 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.